JZT(000989)2022-04-22 16:00Financial Performance - The company's operating revenue for 2021 was CNY 3,784,155,236.54, representing a year-on-year increase of 6.31% compared to CNY 3,559,540,963.73 in 2020[28]. - The net profit attributable to shareholders of the listed company was CNY 270,696,505.84, a decrease of 0.59% from CNY 272,309,874.61 in the previous year[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 240,829,403.36, down 3.67% from CNY 250,004,429.28 in 2020[28]. - The net cash flow from operating activities was CNY 365,912,082.41, a significant decrease of 39.97% compared to CNY 609,555,035.41 in the previous year[28]. - The basic earnings per share for 2021 was CNY 0.3167, a decline of 2.31% from CNY 0.3242 in 2020[28]. - The diluted earnings per share also stood at CNY 0.3167, reflecting the same decrease of 2.31% compared to the previous year[28]. - Total assets increased by 3.83% to CNY 5,265,533,999.97 compared to the previous year[30]. - The company reported a total net profit of CNY 22,305,445.33 from non-recurring gains in 2021[40]. - The total revenue for the year 2021 reached ¥3,784,155,236.54, representing a year-on-year increase of 6.31% compared to ¥3,559,540,963.73 in 2020[85]. - The total revenue for the pharmaceutical industry reached ¥2,716,765,356.38, representing a year-on-year increase of 7.07%[89]. - The gross profit margin for the pharmaceutical industry was 72.90%, a decrease of 2.53% compared to the previous year[89]. Market and Product Development - The company is focusing on innovation and development in the pharmaceutical sector, aligning with national policies to enhance R&D capabilities[46]. - The company achieved sales revenue exceeding 100 million CNY for six products, including Xuexuetong injection and Liuwei Dihuang pill, with An Gong Niu Huang pill's revenue increasing by 22% year-on-year[53]. - The company has developed a series of blood-nourishing products centered around Ejiao, with the market-leading position of Donkey-hide Gelatin Blood-Nourishing Granules[53]. - The company is expanding its strategic layout in the healthcare sector, including the establishment of an internet hospital in Hunan and partnerships with Nanshan Holdings and Beijing Guangda Huichen Elderly Care Services[74]. - The company is enhancing product standards and conducting technical research on 17 products, including Liuwei Dihuang Wan and other traditional Chinese medicine products, to improve technological content and sales channels[72]. - The company is accelerating the development of innovative drugs and health products, with a focus on major, difficult, and rare diseases, while also advancing stem cell product research[140]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a target of completing at least two acquisitions in the next year[166]. Research and Development - The company has a strong focus on research and development, exploring new therapeutic effects of traditional Chinese medicine and developing new product lines[56]. - R&D investment amounted to ¥117,781,782.46 in 2021, an increase of 3.85% from ¥113,419,202.84 in 2020, representing 3.11% of operating revenue[103]. - The number of R&D personnel increased by 3.50% to 325 in 2021 from 314 in 2020, with a slight decrease in the proportion of R&D personnel to total employees from 6.90% to 6.80%[102]. - The company holds over 200 valid patents across various fields, including pharmaceuticals and health products, indicating strong R&D capabilities[62]. - The company completed 16 patent applications and received authorization for 10 patents, including 5 invention patents during the reporting period[73]. Governance and Management - The company maintains an independent operational structure, ensuring separation from the controlling shareholder in aspects such as personnel, assets, and finance[159]. - The company has established a complete procurement, production, sales, and R&D system, demonstrating its independent business capabilities[159]. - The company emphasizes investor relations, utilizing various communication methods to engage with investors and address their concerns[158]. - The company’s governance structure complies with the regulatory requirements set by the China Securities Regulatory Commission[156]. - The company’s board of directors and supervisory board operate independently, ensuring responsible governance and oversight[158]. - The company has established a comprehensive talent training program, focusing on professional and comprehensive skill development to enhance employee capabilities[196]. Strategic Initiatives - The company plans to implement a high-quality development strategy and a health ecology strategy during the 14th Five-Year Plan period[136]. - The company aims to achieve an average annual growth rate of over 8% in operating income and total profit during the 14th Five-Year Plan[135]. - The company is committed to the revitalization and development of traditional Chinese medicine, which has been elevated to a national strategy[135]. - The company is focusing on brand value enhancement and market structure optimization to counteract the risks of price reductions in pharmaceuticals[145]. - The company is prepared to adapt its business strategies in response to ongoing changes in the COVID-19 pandemic situation[148]. Financial Management - The company implemented a cash dividend policy, distributing 4.00 CNY per 10 shares, totaling 342,376,804.80 CNY in cash dividends for the reporting period[199]. - The total distributable profit for the company was 1,481,355,532.56 CNY, with cash dividends accounting for 100% of the total profit distribution[199]. - The company has not made any adjustments to its profit distribution policy during the reporting period, adhering strictly to the provisions of its articles of association[199]. - The company aims to maintain a minimum cash dividend ratio of 20% during profit distribution, considering its growth stage and significant capital expenditure plans[199].